In-vitro-Effekt von Taurolidin auf Plattenepithelkarzinomzellen der Mundhöhle

Petrovic, Ljubinko; Schlegel, K. A.; Ries, Jutta; Park, J.; Diebel, Elke; Schultze‐Mosgau, Stefan; Wiltfang, Jens

doi:10.1007/s10006-003-0452-5

Cited by 12 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately 50-80% of melanoma cells lost their capacity to adhere. In human squamous cell carcinoma (SCC4 and SCC15) a 2-h treatment (0.01-0.5% TRD) significantly reduced cell proliferation and induced apoptosis [26]. The importance of adherence reduction of tumor cells has been described in different animal models.…”

Section: Taurolidine Reduces Tumor Growth In Vitromentioning

confidence: 99%

Taurolidine–a new drug with anti-tumor and anti-angiogenic effects

Jacobi¹,

Menenakos²,

Braumann³

2005

Anti-Cancer Drugs

View full text Add to dashboard Cite

Taurolidine [bis(1,1-dioxoperhydro-1,2,4-thiadiazinyl-4)-methane (TRD)], a product derived from the aminosulfoacid taurin, was first described as an anti-bacterial substance. It was mainly used in the treatment of patients with peritonis as well as antiendoxic agent in patients with systematic inflammatory response syndrome. Meanwhile, quite interesting new experimental findings elucidated several new mechanisms concerning not only antibiotic but also anti-tumor effects. TRD significantly reduces the pathogenicity of prokaryotes, leading to a degeneration of the bacterial wall, and binds free lipoplysaccharides (LPSs) and exotoxins. Furthermore syntheses of tumor necrosis factor-a and interleukin-1b are reduced in LPS-stimulated human macrophages in a dose dependent manner. Tumor angiogenesis is promoted by enhanced expression of all these endogenous angiogenic factors, indicating an anti-angiogenetic effect of TRD. Tumor angiogenesis has a key role in tumor growth. TRD additionally inhibits tumor cell growth by a mitochondrial cytochrome c-dependent apoptotic mechanism, has a direct and elective effect on glial and neuronal brain tumor cells via Fas-ligand-mediated cell death, and inhibits protein synthesis at an early phase of translation, which might explain its various apoptotic effects. Subsequent to these experimental observations, TRD has shown encouraging clinical results after intravenous administration in patients with gastrointestinal malignancies and tumors of the central nerve system. A remarkable experimental observation that comes to complete the above-mentioned findings is the low toxicity on leukopoiesis and erythropoiesis as well as on kidney and liver function in animal models. Several other data confirm low toxicity of the agent after its clinical administration in humans. Prospective clinical studies are currently investigating the efficacy of TRD on local and metastatic tumor growth in different malignancies.

show abstract

Section: Taurolidine Reduces Tumor Growth In Vitromentioning

confidence: 99%

Taurolidine–a new drug with anti-tumor and anti-angiogenic effects

Jacobi¹,

Menenakos²,

Braumann³

2005

Anti-Cancer Drugs

View full text Add to dashboard Cite

show abstract

“…Originally developed for its antibacterial properties, taurolidine has few detrimental effects on normal cells [7] but inhibits cancer cell proliferation [8] and tumor growth by inducing apoptosis [5,9-12] possibly through p53-dependent mechanisms [13]. Taurolidine modulates apoptosis by altering Bcl-2/Bax concentrations [9], and exerts anti-metastatic effects within the tumor microenvironment through inhibition of angiogenesis and endothelial cell adhesion [14].…”

Section: Introductionmentioning

confidence: 99%

The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro

et al. 2013

View full text Add to dashboard Cite

BackgroundOsteosarcoma (OS) affects over 8000 dogs/year in the United States. The disease usually arises in the appendicular skeleton and metastasizes to the lung. Dogs with localized appendicular disease benefit from limb amputation and chemotherapy but most die within 6–12 months despite these treatments. Taurolidine, a derivative of taurine, has anti-tumor and anti-angiogenic effects against a variety of cancers. The following in vitro studies tested taurolidine as a candidate for adjuvant therapy for canine OS. Tests for p53 protein status and caspase activity were used to elucidate mechanisms of taurolidine-induced cell death.ResultsTaurolidine was cytotoxic to osteosarcoma cells and increased the toxicity of doxorubicin and carboplatin in vitro. Apoptosis was greatly induced in cells exposed to 125 μM taurolidine and less so in cells exposed to 250 μM taurolidine. Taurolidine cytotoxicity appeared caspase-dependent in one cell line; with apparent mutant p53 protein. This cell line was the most sensitive to single agent taurolidine treatment and had a taurolidine-dependent reduction in accumulated p53 protein suggesting taurolidine’s effects may depend on the functional status of p53 in canine OS.ConclusionTaurolidine’s cytotoxic effect appears dependent on cell specific factors which may be explained, in part, by the functional status of p53. Taurolidine initiates apoptosis in canine OS cells and this occurs to a greater extent at lower concentrations. Mechanisms of cell death induced by higher concentrations were not elucidated here. Taurolidine combined with doxorubicin or carboplatin can increase the toxicity of these chemotherapy drugs and warrants further investigation in dogs with osteosarcoma.

show abstract

“…It suppresses tumor growth in many cell lines [2,4,10,12,15] and reduces the TNF␣ production in mesangial rat cell cultures [16] and by malignant colonic tumor cells with an IC50 value of 0.5 MM. Additionally, the major pro-angiogenetic factor VEGF production was also reduced within a 6-h contact (IC50 1.5 mM) [5].…”

Section: Discussionmentioning

confidence: 99%

“…Taurolidine (TRD), a synthetic product derived from the aminosulfone acid taurine, consists of two aromatic rings, which are connected with a CH 2 -group [1]. The substance was found to suppress the growth of various abdominal tumor cell lines [2], malignant glioma [3], and human squamous cell carcinoma in vitro and in vivo [4].…”

Section: Introductionmentioning

confidence: 99%